JUNO THERAPEUTICS, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT NOTICE OF GRANT OF RESTRICTED STOCK UNITSRestricted Stock Unit Award Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Washington
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Grant of Restricted Stock Units (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Unit Grant, and any appendices and exhibits attached thereto (all together, the “Award Agreement”).
JUNO THERAPEUTICS, INC. STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANTStock Option Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Washington
Unless otherwise defined herein, the terms defined in the Juno Therapeutics, Inc. 2014 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement including the Notice of Stock Option Grant (the “Notice of Grant”), the Terms and Conditions of Stock Option Grant, and the appendices and exhibits attached thereto (all together, the “Award Agreement”).
JUNO THERAPEUTICS, INC. SECOND AMENDMENT to FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment (this “Amendment”), dated January 29, 2016, to the Fourth Amended and Restated Investors’ Rights Agreement, dated December 5, 2014, and as amended July 27, 2015 (as so amended, the “Agreement”) by and among Juno Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors party thereto, is entered into by and among the Company and each of the Investors set forth on the signature pages hereto. Capitalized terms used but not otherwise defined herein shall have the meanings assigned thereto in the Agreement.
Juno Therapeutics, Inc. Seattle, WA 98109Side Letter Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Reference is made to the letter agreement dated as of October 16, 2013 (the “Original Letter Agreement”), by and between Fred Hutchinson Cancer Research Center (“FHCRC”) and Juno Therapeutics, Inc., f/k/a FC Therapeutics, Inc. (the “Company”) in connection with the Collaboration Agreement, entered into as of the same date (the “Collaboration Agreement”). This amendment to the Letter Agreement (this “Amendment” and, together with the Original Letter Agreement, the “Agreement”) is to confirm the following mutual agreements between the parties:
AMENDMENT NO. 2 TO COLLABORATION AGREEMENTCollaboration Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Collaboration Agreement (the “Amendment No. 2”), effective as of October 16, 2013 (the “Amendment No. 2 Effective Date”), is made by and between Fred Hutchinson Cancer Research Center, a Washington non-profit organization having offices at 1100 Fairview Ave. N., Seattle, WA 98109 (“FHCRC”), and Juno Therapeutics, Inc., a Delaware corporation having offices at 307 Westlake Ave. North, Suite 300, Seattle, WA 98109 (“Juno”).
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Juno Therapeutics, Inc. Seattle, WA 98109Side Letter Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
Reference is made to the letter agreement dated as of November 21, 2013 (the “Original Letter Agreement”), by and between Memorial Sloan-Kettering Cancer Center (“MSKCC”) and Juno Therapeutics, Inc., f/k/a FC Therapeutics, Inc. (the “Company”) in connection with the Master Clinical Studies Agreement, the Master Sponsored Research Agreement and the Exclusive License Agreement, entered into as of the same date (the “Collaboration Agreements”). This amendment to the Letter Agreement (this “Amendment” and, together with the Original Letter Agreement, the “Agreement”) is to confirm the following mutual agreements between the parties:
